

July 12, 2018

To whom it may concern

MSD Animal Health Announcement of Marketing Approval from European Commission for BRAVECTO® Plus for Cats

On July 6, 2018, MSD Animal Health, the veterinary division of Merck & Co., Inc (head office: Kenilworth, N.J., USA, hereinafter called “MSD”) announced that the European Commission has granted marketing authorization in the European Union (EU) for the veterinary medicinal product BRAVECTO® Plus.

BRAVECTO® Plus is a broad-spectrum combination spot-on solution for cats to treat internal and external parasite infestations, such as ticks, fleas, and/or worms that live inside the body. The active pharmaceutical ingredient, fluralaner, which is manufactured and supplied by Nissan Chemical Corporation (head office: Chuo-ku, Tokyo; president: Kojiro Kinoshita) to MSD, provides a quick and persistent flea and tick killing activity lasting for 12 weeks after application, while the active pharmaceutical ingredient, moxidectin, kills parasites present in the body of the cat. BRAVECTO® Plus is effective at preventing heartworm disease for 8 weeks.

BRAVECTO® Plus is a unique addition to the current line-up of BRAVECTO® products, as it can simultaneously treat internal and external parasite infestations, making it a convenient and effective solution for cat owners. According to MSD, ticks, fleas, heartworm, intestinal roundworm and hookworm are listed up as five of the top parasites of concern among veterinarians and cat owners. These parasites can transmit disease not only to the animals, but also to humans through undiagnosed cats. BRAVECTO® Plus addresses these parasites which pose a risk both to animal and human health.

Details of the product are described in the Summary of Product Characteristics (SPC), published by the European Commission (EC)¹ and in the European Public Assessment Report (EPAR) by the European Medicines Agency (EMA)².

Nissan Chemical will continue to respond to the increasing demand of fluralaner from MSD.

¹ Summary of Product Characteristics (SPC) - EC
http://ec.europa.eu/health/documents/community-register/2018/20180508140629/anx_140629_en.pdf

² European Public Assessment Report (EPAR) - EMA
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/veterinary/004440/WC500250113.pdf

[Reference] Timeline of the progress of Nissan Chemical's veterinary medicine business

YEAR	EVENT
2013	First shipment of fluralaner to MSD
2014	BRAVECTO® tablet launched by MSD in EU (Apr.) and U.S. (Jun.)
2015	BRAVECTO® tablet launched from Intervet K.K. ¹ in Japan
2016	BRAVECTO® spot-on for cats launched by MSD in EU (Jul.), in U.S. (Dec.)
2017	BRAVECTO® spot-on for dogs launched by MSD in Germany and Austria (Jan.)
Mar.2017	Increased manufacturing capability of fluralaner (multiple manufacturing sources)
Sep.2017	EXZOLT® launched by MSD in EU

¹Intervet K.K. is a subsidiary of Merck & Co., Inc. in Japan.

About MSD Animal Health

MSD Animal Health, known as Merck Animal Health in the United States and Canada, is the global animal health business unit of MSD. Through its commitment to the *Science of Healthier Animals™*, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets.

Contact information for inquiries on the above

<p>Nissan Chemical Corporation Corporate Planning Department CSR & Public Relations Office E-mail: csr_pr@nissanchem.co.jp</p>
